At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)
In Brief
A Phase 2 clinical trial evaluating HMPL-760 planned dose 1, R-GemOx, and 3 other interventions for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Active but no longer recruiting, targeting 61 participants across 16 sites.
Detailed Summary
The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
Study Details
Timeline
Interventions
HMPL-760 planned dose 1 daily (QD) orally
R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
HMPL-760 placebo planned dose 1 daily (QD) orally
HMPL-760 planned dose 2 daily (QD) orally
HMPL-760 placebo planned dose 2 daily (QD) orally